Abstract
148P DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have